🆕The regulatory framework for cancer treatments is overly restrictive and may stifle innovation.

The Biotechnology Innovation Organization has stated that the regulatory framework for cancer treatments is overly restrictive and may stifle innovation. A study published in the Journal of Clinical Oncology found that the regulatory framework for cancer treatments can be slow and bureaucratic, which may delay the approval of new and effective therapies.